Angiex Begins Patient Dosing in Phase 1 Trial of AGX101

10 August 2024

Angiex Initiates Phase I Clinical Trial for Groundbreaking Cancer Therapy AGX101

Angiex has officially launched its Phase I clinical trial for AGX101, a novel TM4SF1-targeted antibody-drug conjugate (ADC) therapy. This trial represents a critical milestone in Angiex’s mission to develop innovative cancer treatments, as AGX101 aims to target the blood vessels that feed aggressive tumors. The study will assess the safety and potential efficacy of this first-in-class therapy, bringing Angiex closer to offering new options for patients with difficult-to-treat cancers.

Pharmabiz, a leading news outlet covering the pharmaceutical and healthcare industries in India and beyond, reported on this significant development. Their coverage underscores the global interest in pioneering cancer therapies and the potential impact of AGX101 in addressing unmet medical needs. As a trusted source of industry news, Pharmabiz highlights the importance of such trials in the broader context of drug development and innovation.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch